Description: This session will provide an overview of the landscape of accident and health insurance valuation. Attendees will gain an understanding of key concepts and various actuarial techniques employed in the valuation of accident and health insurance policies. By incorporating real-world perspectives and experiences, this presentation equips attendees with actionable knowledge to enhance their understanding and approach to accident and health valuation in an ever-evolving insurance landscape.

Description: June 2024, AG54 will begin for new RILA sales. This guidance requires companies to determine an interim value that is more aligned with the market value of the position on a daily basis. This discussion will talk through companies adoption of AG54, lessons learned, approaches and integration with the administration system. Additionally this session will discuss how AG54 impacts new product design, reserving and capital implications.

Description: This session will cover the latest information on annuity products. It will cover sales levels, product features, and pricing trends. It will also cover latest regulation effects on products and pricing. It will give the audience a well-rounded view of the annuity market and the current environment.

Description: Actuaries are increasingly being asked to incorporate Economic Scenario Generators into their work. Whether it be a Risk Neutral model for pricing or a Real-World version for Economic Capital modelling, using these tools can help produce a much more robust analysis. Unfortunately, these models and their underpinnings are also very complicated, which can lead to confusion. Come watch the presenters try to demystify some of this. In particular, they will address the following questions: • What is the difference between Real-World and Risk Neutral scenarios? • When should I use one or the other? • How are these models calibrated? • What are some of the misconceptions about these models? At the conclusion of the session, attendees will be able to: • Explain the difference between Real-World and a Risk Neutral scenarios • Understand the appropriate usage of both • Identify some of the calibration questions that go into developing an appropriate set of scenarios • Avoid some of the common misconceptions about these scenarios

Description: In this session, presenters will share the impacts of transition to IFRS 17 on equity and various KPIs across insurance companies (Life & P&C), as well as share some observations of what the IFRS 17 landscape looks like across different global regions. The session will conclude with lessons learned and expectations for emerging practices under IFRS 17 globally.

Description: With large public filers having adopted LDTI in 2023, company practices are continuing to evolve as it relates to experience monitoring, assumption unlocking, as well as both internal and external communication and disclosures related to assumptions. In this diverse session featuring representatives from both insurance companies as well as industry analysts, we'll explore how companies approach emerging experience in a given year through a case study approach. The moderator will explore various topics such as off-cycle experience monitoring, experience outliers, simplifications and approximations, and materiality considerations. Each 'what-if' scenario will start with a prompt from the moderator, discussion among the industry panelists as to how they would approach the situation within their own organization, followed by commentary from the analysts as to how they might expect companies to respond in each case. Audience participation will be encouraged to explore potential alternative approaches in an engaging, interactive session.

Description: Gain a high-level understanding on how long-duration targeted improvement (LDTI) impacts insurance products and earnings. Explore highlights on secondary impacts to companies due to additional complexity of LDTI, such as a need for a source of earnings analysis. Then dive into the details and hear an explanation on how earnings emergence differs for each type of life and annuity product impacted by LDTI. Finally, discuss the impact -to-earnings volatility under LDTI for each product type. Close the session by connecting how the investor story changes with all the impacts discussed during the session.You should walk away with a good understanding of LDTI earnings emergence, which is a topic that has very limited thought leadership available today.

Description: Join a discussion on the tax implications for direct writers ceding annuity blocks for both onshore and offshore reinsurance arrangements. Get an introduction to the tax consequences of the risk transfer of annuity features and guarantees to reinsurers to reinsurers that are U.S.-based and not U.S. domiciled.

Description: In the time since the original proposal to move healthwriting companies from the blue blank to the orange blank, there have been several incremental updates to the blue blank by the NAIC Blanks Working Group to integrate portions of the orange blank into the blue blank. Meanwhile, the NAIC RBC Working Group has issued their proposal to change the health test for comment and appear to be moving forward with the proposal to revise the health test. This would obligate companies that write predominantly health business onto the orange blank rather than the blue blank, which they have historically used for reporting. Discover background of the revised health test, the incremental updates to the blue blank that have been implemented recently, additional incremental updates proposed for upcoming blue blanks, and the current status of the Health RBC Working Group proposal to revise the health test. Hear observations about companies that have opted to 'take the plunge' and move to the orange blank ahead of the revised health test as well as companies that have opted to remain on the blue blank and incrementally update as new requirements are integrated into the Blue blank. By attending the session, you will be able to: • Understand the context of the initiative to revise the NAIC health test. • Summarize the recent changes to the blue blank implemented by the Blanks Working Group that integrate portions of the orange blank into the blue blank. • Summarize the upcoming proposed changes to the blue blank by the Blanks Working Group that integrate additional portions of the orange blank into the blue blank. • Summarize the current status of the Health RBC Working Group proposal to revise the health test. • Provide industry perspective on companies that have opted to move to the orange blank ahead of the revised health test and companies that have opted to remain on the blue blank until the NAIC requires it.

Description: S&P Global published a revised insurance capital model in November 2023. The revisions add considerable complexity to their insurance capital model and rely more on companies to fill out the detailed model inputs. In return, the new model allows for better risk differentiation and an overall better assessment of insurance company risk-adjusted capitalization. In this session we will review the new capital model in-depth, considering its implications for capital management and product development. By the end of the session, attendees should have a deeper understanding of the revised criteria of the S&P insurance capital model, including its most important risk drivers and how it relates to the AM Best 'BCAR' and the NAIC RBC capital models.